Publikationer av / inom följande

2012

Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis — an inception cohort study.

Ajeganova S, de Faire U, Jogestrand T, Frostegård J, Hafström I.J Rheumatol. 2012 Jun;39(6):1146-54. doi: 10.3899/jrheum.111334. Epub 2012 May 15.PMID: 22589258

Psychometric properties of the Swedish Rheumatic Disease Empowerment Scale
Arvidsson S, Bergman S, Arvidsson B, Fridlund B, Tingström P.
Musculoskeletal Care. 2012 Jun;10(2):101-9.

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, Chatzidionysiou K, Bratt J; Swefot study group. Lancet. 2012 May 5;379(9827):1712-20.

Education and benchmarking among physicians may facilitate sick-listing practice.

Bremander AB, Hubertsson J, Petersson IF, Grahn B.
J Occup Rehabil. 2012 Mar;22(1):78-87. doi: 10.1007/s10926-011-9321-5.PMID: 21769594

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.

Rezaei H, Saevarsdottir S, Forslind K, Albertsson K, Wallin H, Bratt J, Ernestam S, Geborek P, Pettersson IF, van Vollenhoven RF. Ann Rheum Dis. 2012 Feb;71(2):186-91.

Cookie-samtycke med Real Cookie Banner